Denali Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
DNLI$20.33+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $387,626 | $205,326 |
| Short-term marketable securities | 600,058 | 662,553 |
| Prepaid expenses and other current assets | 35,068 | 32,779 |
| Total current assets | 1,022,752 | 900,658 |
| Long-term marketable securities | 63,785 | 98,322 |
| Property and equipment, net | 51,728 | 52,402 |
| Finance lease right-of-use asset | 47,616 | 48,531 |
| Operating lease right-of-use asset | 17,922 | 19,002 |
| Intangible asset, net | 36,000 | — |
| Other non-current assets | 26,220 | 25,939 |
| Total assets | $1,266,023 | $1,144,854 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $40,380 | $505 |
| Other accrued costs and current liabilities | 69,776 | 97,846 |
| Total current liabilities | 110,156 | 98,351 |
| Operating lease liability, less current portion | 24,680 | 27,210 |
| Finance lease liability, less current portion | 5,508 | 5,532 |
| Liability related to the revenue participation right agreement | 199,581 | — |
| Total liabilities | 339,925 | 131,093 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity: | ||
| Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 158,656,318 shares and 156,182,177 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 1,913 | 1,888 |
| Additional paid-in capital | 3,104,838 | 3,062,715 |
| Accumulated other comprehensive income (loss) | (682) | 682 |
| Accumulated deficit | (2,179,971) | (2,051,524) |
| Total stockholders' equity | 926,098 | 1,013,761 |
| Total liabilities and stockholders’ equity | $1,266,023 | $1,144,854 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.